I.A. APHANASYEV, N.M. NIKITINA, A.P. REBROV

Saratov State Medical University named after V.I. Razumovskiy, 112 Bolshaya Kazachya St., Saratov, Russian Federation 410012

Aphanasyev I.A. — postgraduate student of the Department of hospital therapy of the medical faculty, tel. (845) 249-14-37, e-mail: iafanasyev88@yandex.ru

Nikitina N.M. — D. Med. Sc., Assistant of the Department of hospital therapy of the medical faculty, tel. (845) 249-14-37, e-mail: nikina02@yandex.ru

Rebrov A.P. — D. Med. Sc., Professor, Head of the Department of hospital therapy of the medical faculty, tel. (845) 249-14-37, e-mail: andreyrebrov@yandex.ru

In this review are presented the major risk factors for development of cardiovascular pathology in patients with rheumatoid arthritis (RA). There is provided the background information on modern drugs used for treatment of RA (glucocorticoids, nonsteroidal anti-inflammatory drugs, anti-synthetic basis and genetically engineered biological drugs), described their role in determining cardiovascular risk in patients with RA. There was concluded that adequate treatment of patients with RA, in accordance with the concept «Treatment until the goal is reached» can contribute to a significant reduction in the risk of cardiovascular disease.

Key words: rheumatoid arthritis, cardiovascular pathology, rheumatoid arthritis therapy, inflammation, genetically engineered biological therapy.

REFERENCES

1. Smolen J.S., Aletaha D., Bijlsma J.W. et al. Treating rheumatoid arthritis to target. R. recommendations of an international task force. Ann Rheum Dis., 2010, vol. 69 (4), rr. 631-637. doi:http:.dx.doi.org/10.1136/ard.2009.123919.
2. Smolen J.S., Landewe R., Breedveld F.C. et al. EULAR recomendattions for the management of rheumatoid arthritis with syntethetic and biological disease – modifying antirheumatic drugs. Ann Rheum Dis., 2013:0:1-18. doi:10.1136/annrheumdis-2013-204573.
3. Karateev D.E., Luchikhina E.L., Demidova N.V. et al. Pervoe rossiyskoe strategicheskoe issledovanie farmakoterapii revmatoidnogo artrita (remarka): Rezul’taty lecheniya 130 bol’nykh v techenie 12 mesyatsev [The first Russian strategic study of pharmacotherapy of rheumatoid arthritis (remark): Results of treatment of 130 patients for 12 months.].
4. Avina-Zubieta J.A., Choi H.K., Satdatsafavi M. et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum., 2008, vol. 59 (12), rr. 1690-7.
5. Edwards C.J., Syddall H., Goswami R., et al. The autoantibody rheumatoid factor may be an independent risk factor for ischemic disease in men. Heart, 2007, Oct., vol. 93 (10), rr. 1263-1267. doi:10.1136/hrt.2006.097816.
6. Lopez Longo F.J., Oliver Minarro D. De la Torre I. et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Care and Research., 2009, vol. 61 (4), rr. 419-424.
7. Kaplan M.J. Cardiovascular complications of rheumatoid arthritis – assessment, prevention and treatment. Rheum. Dis. Clin. North Am., 2010, vol. 36 (2), rr. 405-426. doi:10.1016/j.rdc.2010.02.002.
8. Davis J.M. 3rd, Roger V.L., Crowson C.S. et al. The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population. Arthritis Rheum., 2008, vol. 58 (9). rr. 2603-2611 doi:10.1002/art.23798.
9. Lévy l., Fautrel B., Barnetche T., Schaeverbeke T. Incidence and risk of fatal myocardial infarction and stroke events in rheumatoid arthritis patients. A systematic review of the literature. Clin Exp Rheumatol., 2008, vol. 26, rr. 673-679.
10. Maradit-Kremers H., Nicola P.J., Crowsoon C.S. et al. Cardiovascular death in rheumatoid arthritis. Arthritis Rheum., 2005, vol. 52, rr. 722-732. doi:10.1002/art.20878.
11. Popkova T.V., Novikova D.S., Nasonov E.L. Atherothrombosis in autoimmune diseases: current state of the problem. Consilium medicum, 2008, vol. 10 (11), rr. 128-35 (in Russ.).
12. Chung C.P., Giles J.T., Petri M. et al. Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with controlsubjects from the multi-ethnic study of atherosclerosis. Semin Arthritis Rheum., 2012, vol. 41 (4), rr. 535-44.
13. Meek I.L., Picavet H.S., Vonkeman H.E. et al. Increasedcardiovascular risk factors in different rheumatic diseases with the general population. Oxford (United Kingdom). Rheumatology, 2012.
14. Wallberg-Jonsson S., Johansson H., Ohman M.X. et al. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol., 1999, Dec., vol. 26 (12), rr. 2562-71.
15. Wallberg-Jonsson S., Ohman M.X., Dahlqvist S.R. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern. J. Rheumatol., 1997, vol. 24, pp. 445-451.
16. Myasoedova E., Crowson C.S., Maradit-Kremers H. et al. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis., 2010, vol. 69, rr. 1310-1314 doi:10.1136/ard.2009.122374.
17. Chung C.P., Oeser A., Avalos I. et al. Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res. Ther., 2006, vol. 8(6). R. 186. doi:10.1186/ar2098.
18. Woods A., Brull D.J., Humphries S.E., Montgomery H.E. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur. Heart. J., 2000, vol. 21. pp. 1574-1583. doi: http://dx.doi.org/10.1053/euhj.1999.2207 1574-158.
19. Libby P., Ridker P.M. Novel inflammatory markers of coronary risk. Circulation, 1999, vol. 100, pp. 1148-1150.doi:10.1161/01.CIR.100.11.11481.
20. Rader D.J. Inflammatory markers of coronary risk. N. Engl. J. Med., 2000, vol. 343, pp. 1179-1182. doi:10.1056/NEJM200010193431609.
21. Jialal I., Devaraj S., Venugopal S.K. C-reactive protein. R. risk or mediator in atherogenesis? Hypertension, 2004, vol. 44, pp. 6-11.
22. Devaraj S.1., Kumaresan P.R., Jialal I. C-reactive protein induces release of both endothelial microparticles and circulating endothelial cells in vitro and in vivo: further evidence of endothelial dysfunction. Clin Chem. 2011, Dec., vol. 57(12), rr. 1757-61. doi: 10.1373/clinchem.2011.169839.
23. Pober J.S., Cotran R.S. Cytokines and endothelial cell biology. Phyciol. Rev., 1990, vol. 70, pp. 427-451.
24. Cohn J.N., Quyyumi A.A., Hollenberg N.K., Jamerson K.A. Surrogate markers for cardiovascular disease: Functional markers. Circulation, 2004, vol. 109, rr. IV-31-IV-46. doi:10.1161/01.CIR.0000133442.99186.39.
25. Makol A., Wringht K., Matterson E.L. Safe use of antirheumatic agents in patients with comorbidities. Rheum. Dis.Clin. N. Am., 2012, vol. 38, rr. 771-793 doi.org/10.1016/rdc.2012.08.013.
26. Konstam M.A., Weir M.R., Reicin A. et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation, 2001, vol. 104(19), pp. 2280-2288
27. Trelle S., Reichenbach S., Wandel S. et al. Cardiovascular safety of non –steroidal anti-inflammatory drugs: network meta-analysis. BMJ, 2011, 342, rr. c7086. doi:10.1136/bmj.c7086.
28. Maxwell S.R., Moots R.J., Kendall M.J. Corticosteroids. R. do they damage the cardiovascular system? Postgrad. Med. J., 1994, vol. 70, pp. 863-870.
29. Mosshich V.P., Kichko A.S. Pathogenetic mechanisms of atherogenesis in patients with rheumatoid arthritis. Vrachebnoe delo, 1989, no. 5, rr. 34-36. 30 (in Russ.).
30. Park Y.B., Ahn S.W., Choi H.K. et al. Atherosclerosis in rheumatoid arthritis. R. morphologic evidence obtained by carotid ultrasound. Arthritis. Rheum., 2002, vol. 46, pp. 1714-1719. DOI:10.1002/art.10359.
31. Boers M., Nurmohamed M.T., Doelman C.J.A. et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis., 2003, vol. 62, rr. 842-845 doi:10.1136/ard.62.9.842.
32. Slot O. Changes in plasma homocysteine in arthritis patients starting treatment with low-dose methotrexate subsequently supplemented with folic acid. Scand. J. Rheumatol., 2001, vol. 30(5), pp. 305-307.
33. Morgan S.L., Baggott J.E., Lee J.Y. et al. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J. Rheumatol., 1998, vol. 25, pp. 441-446.
34. Mangoni A.A., Sherwood R.A., Asonganyi B. et al. Short-term oral folic acid supplementation enhances endothelial function in patients with type 2 diabetes. Am. J. Hypertens., 2005, vol. 18, pp. 220-226 doi:10.1016/j.amjhyper.2004.08.036.
35. Medved’ E.E., Dubikov A.I., Belogolovykh L.A. Effect of methotrexate and leflunomide on the cytokine profile and metabolism of nitric oxide in patients with rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya, 2006, no. 4, pp. 58-62 (in Russ.).
36. Chan E.S.L., Cronstein B.N. Molecular action of methotrexate in inflammatory disease. Arthr. Res., 2002, l.4, pp. 266-273.
37. Wyatt A.W., Steinert J.R., Wheeler-Jones C.P.D. et al. Early activation of the p42/p44 pathway mediates adenosine-induced nitric oxide production in human endothelial cells: a novel calcium-insensitive mechanism. Faseb. J., 2002, vol. 16, pp. 1584-1594.
38. Bottcher M., Buus N., Hermansen F. et al. Influence of nitric oxide synthase and adrenergic inhibition on adenosine-induced myocardial hyperemia. Circulation, 2001, vol. 104(19), pp. 2305-2310. doi:10.1161/hc4401.098293.
39. Wallace D.J., Metzger A.L., Stecher V.J. et al. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am. J. Med., 1990, vol. 89, no. 3, pp. 322-326.
40. Munro R., Morrison E., McDonald A.G. et al. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann. Rheum. Dis., 1997, vol. 56, pp. 374-377.
41. Wallace D.J., Linker-Israeli M., Metzger A. et al. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus, 1993, vol. 2, suppl. 1, pp. S13-S1.
42. Haas R.M., Li P., Chu J.W. Glucose-lowering effects of sulfasalazine in type 2 diabetes. Diabetes Care, 2005, 28(9), rr. 2238-2239. doi:10.2337/diacare.28.9.2238.
43. Singh J.A., Furst D.E., Bharat A. et al. 2012 update of the 2008 American College of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res., 2012, vol. 64(5), rr. 625-39. doi:10.1002/acr.21641.
44. Raterman H.G., Levels H., Voskuyl A.E. et al. HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab. Ann Rheum Dis., 2013, Apr., vol. 72(4), rr. 560-5. doi: 10.1136/annrheumdis-2011-201228.
45. Maxwell L., Singh J.A. Abatacept for rheumatoid arthritis. Cohrane Database Syst Rev., 2009. vol. 4, r. 7277. doi:10.1002/14651858.CD007277.pub2.
46. Hingorani A.D., Casas J.P. The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomization analysis. Lancet, 2012, vol. 379(9822), rr. 1214-1224. doi:10.1016/S0140-6736(12)60110-X.
47. Genovese M.C., Rubbert-Roth A., Smolen J.S. et al. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J. Rheumatol., 2013, vol. 40(6), rr. 768-80. doi:10.3899/jrheum.120687.